摘要目的 探讨连花清瘟颗粒联合阿比多尔治疗新型冠状病毒肺炎(COVID-19)的疗效。方法 收集2020年2月17日~3月6日武汉市第三人民医院收治的COVID-19患者295例,随机分为2组,对照组(n=148)予以阿比多尔口服治疗,观察组(n=147)予以连花清瘟颗粒联合阿比多尔。比较两组治疗前后中医证候积分、外周血白细胞计数(WBC)、淋巴细胞计数(LYM)、C反应蛋白(CRP)、降钙素原(PCT)及胸部CT复查改善情况。结果 观察组总有效率明显高于对照组(80.95% vs 64.86%),转重症率明显低于对照组(14.29% vs 23.65%),差异均有统计学意义(P<0.05)。治疗7 d后,观察组主要中医证候积分(发热、乏力、咳嗽、咽干咽痛及胸闷)及CRP、PCT水平明显低于对照组(P<0.05),WBC、LYM明显高于对照组(P<0.05)。观察组胸部CT疗效有效率为69.39%,高于对照组的62.84%,但差异无统计学意义(P>0.05)。两组均无严重药物相关性不良反应。结论 连花清瘟颗粒联合阿比多尔治疗能够有效缓解轻度COVID-19患者临床症状,调节相关炎症因子表达,提高疗效,降低转重症率。
Abstract：OBJECTIVE To discuss the effects of Lianhua Qingwen granules plus arbidol on treatment of mild corona virus disease-19 (COVID-19). METHODS A total of 295 COVID-19 patients (2020.2.17-2020.3.6) in Wuhan Third Hospital were chosen and randomly assigned to control group (n=148) and observation group (n=147). The control group orally took arbidol and the observation group took Lianhua Qingwen granules and arbidol. TCM symptom scores, white blood count (WBC), lymphocyte count (LYM), C-reactive protein (CRP), procalcitonin (PCT) and chest CT review conditions were compared. RESULTS Total effective rate in the observation group was significantly higher than control group ((80.95% vs. 64.86%); severe transfer rate in the observation group was lower than control group (14.29% vs. 23.65%) (P＜0.05); after 7 d of treatment, TCM syndromes like fever, weakness, cough, throat dryness and sore and chest discomfort, CRP and PCT levels in the observation group were significantly lower than control group (P＜0.05); WBC and LYM levels in the observation group were significantly higher than control group (P＜0.05); based on CT review, effective cure rate in the observation group (69.39%) and control group (62.84%) was not significantly different (P＞0.05). Both of groups had no serious adverse reactions. CONCLUSION Lianhua Qingwen granules combined with arbidol can relieve the clinical symptoms, adjust the inflammatory factors, increase the curative effects and reduce the severe transfer rate.
余平, 李叶子, 万少兵, 王瑛. 连花清瘟颗粒联合阿比多尔治疗轻度新型冠状病毒肺炎的疗效观察[J]. 中国药学杂志, 2020, 55(12): 1042-1045.
YU Ping, LI Ye-zi, WAN Shao-bing, WANG Ying. Effects of Lianhua Qingwen Granules Plus Arbidol on Treatment of Mild Corona Virus Disease-19. Chinese Pharmaceutical Journal, 2020, 55(12): 1042-1045.
National Health and Health Commission.the most new type situation about coronavirus up to 24:00 March 12.[R]. (2020-3-12).
National Health and Health Commission.Diagnosis and treatment plant of coronavirus pneumonia(Trial sixty edition )[S]. 2020.
SHANMUGRAJ B, SIRIWATTANANON K, WANGKANONT K, et al. Perspectives on Monoclonal Antibody Therapy as Potential Therapeutic Intervention for Coronavirus disease-19 (COVID-19).[J]. Asian Pac J Allergy Immunol, 2020,38(1):10-18.
SHA M C. Consistency evaluation method for Lianhua Qingwen Capsule based on microcalorimetry[J]. Chin Tradit Herb Drugs(中草药),2017, 48(11):2202-2206.
WANG S H, LIU J F, ZHANG Y L, et al. Systematic review of efficacy and safety of Lianhua Qingwen Capsules in treatment of viral influenza[J]. China J Chin Mater Med(中国中药杂志), 2019,44(7):113-117.
CHAN J F, KOK K H, ZHU Z, et al. Genomic Characterization of the 2019 Novel Human-Pathogenic Coronavirus Isolated From a Patient With Atypical Pneumonia After Visiting Wuhan.[J]. Emerg Microbes Infect, 2020,9(1):221-236.
SFDA. Guiding Principles for Clinical Research of New Chinese Medicine.(The 2010 Revision)[中药新药临床研究指导原则(2010年修订)][M]. Beijing: China Medical Science and Technology Publlishing, 2002:186.
Professional committee of infection and inflammation radiology of Chinese research hospital association. Guidelina for medical inaging in auxliary diagnasis of coronavirus disease 2019[J]. Chin J Med Imaging Technol(中国医学影像技术), 2020,36(3):321-331.
CHAN J F, YUAN S, KOK K H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.[J]. Lancet, 2020, 395(10223):514-523.
ZHANG L, LIU Y. Potential Interventions for Novel Coronavirus in China: A Systematic Review[J]. J Med Virol, 2020, 92(5):479-490.
LI J Y, YOU Z, WANG Q,et al. The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future[J]. Microbes Infect, 2020, 22(2):80-85.
QU X K, HAO L L, MA J H, et al. Observation on clinical effect of Shufeng Jiedu Capsule combined with Arbidol Hydrochloride Capsule in treatment of COVID-19 [J]. Chin Tradit Herb Drugs(中草药),2020,51(5):1167-1170.
LU R, ZHAO X, LI J,et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding[J]. Lancet, 2020,395(10224):565-574.
PAYBAST S, EMAMI A, KOOSHA M, et al. Novel Coronavirus Disease (COVID-19) and Central Nervous System Complications: What Neurologist Need to Know[J]. Acta Neurol Taiwan, 2020, 29(1):24-31.
SUN S J, LIANG T, LU Y, et al. Study on the effects of Langchuangqing Granule on systemic lupus erythematosush in animals[J]. Chin J Clin Pharmacol, 2016, 32(12):1125-1128.
CHEN G, GUANG H M, LI L, et al. Biological network analysis on mechanism of Lianhua Qingwen Granules/Capsules for H1N1 influenza A[J]. J Tradit Chin Med(中医杂志), 2014,55(8):703-707.
ZHOU G, ZHAO Q. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2.[J]. Int J Biol Sci, 2020,16(10):1718-1723.
GUAN X D, LIU Z M. 2013《guidelines for the diagnosis, prevention and treatment of ventilator-associated pneumonia》[J]. Nat Med J China(中华医学杂志),2014, 94(5):333-334.
JI G H, HUANG M H, ZHANG Q, et al. CT manifestations and dynamic changes of corona virus disease 2019[J]. Chin J Med Imaging Technol(中国医学影像技术), 2020,36(2):242-247.
GUO Y R, CAO Q D, HONG Z S, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status.[J]. Mil Med Res, 2020, 7(1):11.
YANG Y, SHIN W I, PANG Y X, et al. The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment.[J]. Int J Environ Res Public Health, 2020,17(7):2323.